Inactive Instrument

Lonza Group Ltd Stock Other OTC

Equities

LZAGY

US54338V1017

Biotechnology & Medical Research

Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site

Financials

Sales 2024 * 6.66B 7.4B 10.06B Sales 2025 * 7.62B 8.47B 11.51B Capitalization 38.38B 42.63B 57.97B
Net income 2024 * 886M 984M 1.34B Net income 2025 * 1.1B 1.22B 1.66B EV / Sales 2024 * 6.18 x
Net Debt 2024 * 2.79B 3.1B 4.21B Net Debt 2025 * 3.4B 3.78B 5.13B EV / Sales 2025 * 5.48 x
P/E ratio 2024 *
43.4 x
P/E ratio 2025 *
34.6 x
Employees -
Yield 2024 *
0.85%
Yield 2025 *
0.98%
Free-Float 95.87%
More Fundamentals * Assessed data
Dynamic Chart
Managers TitleAgeSince
Chief Executive Officer 72 17-04-24
Director of Finance/CFO 52 21-11-30
Chief Operating Officer 55 22-07-31
Members of the board TitleAgeSince
Director/Board Member 63 14-04-15
Director/Board Member 66 14-04-15
Director/Board Member 58 22-05-04
More insiders
Lonza Group AG is one of the world leaders of the development, production and marketing of chemical products. Net sales break down by family of products and services as follows: - bio-pharmaceuticals (52.6%): exclusive syntheses, microbiological fermentation products , mammalian cell cultures, etc.; - capsules and dosing solutions for biopharmaceuticals, drugs and nutrition products (20.3%). In addition, the group offers nutritional ingredients; - small molecule drug substances (13.2%); - technologies and platforms for manufacturing processes and production of cell and gene therapies (11.1%); - other (2.8%). Net sales are distributed geographically as follows: Switzerland (16%), Europe (29.8%), the United States (38.8%), the Americas (3%), Japan (3.7%), China (2.6%), Asia (5.8%) and other (0.3%).
Calendar
More about the company
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW